Latest Content

Ziftomenib Submits New Drug Application to FDA for R/R NPM1-Mutant AML

April 13th 2025, 6:00pm

By Alex Biese

Article

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

Phase 3 Trial Leads to FDA Approval of Cabometyx in Neuroendocrine Tumors

April 13th 2025, 2:00pm

By Dr. Jennifer Chan

Video

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors.

NeuroSAFE May Preserve Erectile Function After Prostate Cancer Surgery

April 12th 2025, 6:00pm

By Alex Biese

Article

Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.

First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

April 12th 2025, 2:00pm

By Alex Biese

Article

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

Imdelltra May Improve Survival in Small Cell Lung Cancer

April 11th 2025, 9:00pm

By Alex Biese

Article

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

A Kidney Cancer Advocate Shares Advice for Newly Diagnosed Patients

April 11th 2025, 8:00pm

By Sid Salder

Video

Some cancer statistics may reflect 'backwards-looking data', making it important to stay up to date on reliable information and happenings in the space.

Knowing the Signs to Detect and Treat Testicular Cancer Early

April 11th 2025, 7:00pm

By Ryan Scott

Article

Testicular cancer is rare but highly curable, especially with early detection; treatment varies by stage, and follow-up care supports long-term health.

Spring Forward: How I Stay Grounded and Hopeful with Lynch Syndrome

April 11th 2025, 5:00pm

By Georgia Hurst

Article

Living with Lynch isn't easy, but it's not all doom and gloom. It's a call to live deliberately.

FDA Approves Opdivo Plus Yervoy for Advanced HCC

April 11th 2025, 3:06pm

By Alex Biese

Article

The FDA has approved Opdivo with Yervoy for the first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma.

What Role May ctDNA Have in Melanoma Management?

April 11th 2025, 1:00pm

By Dr. Michael K. Wong

Article

CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.

An Expert Breaks Down Lymphedema Following Cancer Care

April 10th 2025, 9:00pm

By Dr. Sheri Prentiss

Video

Dr. Sheri Yolanda Prentiss discusses the importance of seeking early intervention to detect lymphedema following cancer care.

Melanoma Taught Me Faith, Gratitude and That Nothing Is Permanent

April 10th 2025, 8:00pm

By Starr Crutcher

Article

I was diagnosed with stage 3 melanoma at 31, faced recurrence and now share my journey to raise awareness, stay hopeful and trust in God’s plan.

FDA Approves Avastin Biosimilar Jobevne Across Several Cancer Types

April 10th 2025, 7:00pm

By Alex Biese

Article

The FDA has approved Jobevne, a biosimilar to Avastin, for IV use in a number of cancer types.

Managing Cancer Demands With Flexibility and a Strategic Mindset

April 10th 2025, 5:00pm

By Andy Winnegar

Article

It isn’t easy having cancer. But like gardening in a harsh climate, survival and growth come from strategies, adaptation, and patience.

FDA Grants Full Approval to Vitrakvi For NTRK-Positive Solid Tumors

April 10th 2025, 2:47pm

By Alex Biese

Article

Vitrakvi, first granted accelerated approval in 2018, has received full approval from the FDA.